Navigation Links
Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
Date:3/4/2008

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the Food and Drug Administration ("FDA") has cleared its 510(k) submission for its Plexur M(TM) Biocomposite. Adapting the Company's proprietary Plexur(R) Technology, Plexur M(TM) is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M(TM) is remodeled and replaced by host bone.

Plexur M(TM) is a uniquely flexible biomaterial composed of mineralized cortical fibers bound in a resorbable polymer. When heated, this biocomposite becomes moldable and pliable allowing a surgeon numerous options for use during surgery. During the cooling process, Plexur M(TM) hardens providing a versatile porous scaffold to assist in regeneration of damaged and diseased bones. It is an ideal medium for placing screws with no cracking or resultant particulate shedding and can be reamed and reverse-reamed without dislodging the graft or damaging the surrounding bone. Plexur M(TM) uses proprietary processing steps that have been shown to inactivate viruses and is terminally sterilized.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased to be able to introduce the Plexur M(TM) Biocomposite. Our internal team has done an excellent job to develop this product and receive FDA clearance for orthopedic applications. We anticipate filing an additional 510(k) submission for the use of Plexur M(TM) in spinal applications in the first part of the second quarter. We plan to continue our research and development activitie
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
2. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech to Present at Sidoti Conference in San Francisco
5. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
6. Ventria Receives Friends of Education Award From Geary County School District
7. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
8. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
9. Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... from the University of Leicester has furthered our ... potential to create new materials using nanosized ,building ... in the prestigious academic journal Physical Review ... examine in rich detail the structure and internal ... acetylene molecule and a single helium atom. , ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... CBI is pleased to announce the full agenda for ... Access Congress, being held December 6-7, 2011 in Philadelphia, ... Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic ... Anchored by conference chairman, Robert Besthof, Vice President, ...
... -- Third ocular product partnered with Sanofi approved ... plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the ... Food and Drug Administration (FDA) has approved its Investigational ... development of UshStat ® , a novel gene-based treatment ...
... TRIANGLE PARK, N.C., Oct. 17, 2011 Max Neeman ... hemophilia trials according to the Clinical Trials Registry-India (CTRI). ... India, Max Neeman can boast supporting 80% of these ... International has established a team of experts specialized in ...
Cached Biology Technology:Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 3Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 4CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India 2
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
(Date:7/24/2014)... The planet,s current biodiversity, the product of 3.5 billion ... in the history of life. But it may be ... of scientific literature and analysis of data published in ... that the loss and decline of animals is contributing ... the planet,s sixth mass biological extinction event. , Since ...
(Date:7/24/2014)... terroir, meaning the microbial populations found on surfaces in ... the final flavor according to research published ahead of ... . This is the first time investigators have taken ... Many sake makers inoculate with both bacteria and yeast, ... of California, Davis, but he and his colleagues investigated ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2
... the University of Georgia, using glow-in-the-dark proteins and ... of a complex organelle in the bacterium that ... in new, precise detail the unique cell extension ... Mycoplasma pneumoniae. This structure, called a "terminal organelle," ...
... fruit flies, developmental biologists at the Kimmel Cancer Center ... a new way that genes are turned on and ... processes are at work in higher organisms, including mammals, ... understanding of a range of diseases, including childhood cancer. ...
... prevents the production of a critical blood-clotting protein. Treatments ... exist, may consist of risky blood transfusions or expensive ... be induced to begin producing these proteins, say by ... , Prof. Yair Reisner and Ph.D. student Anna Aronovich ...
Cached Biology News:UGA scientists unravel 'molecular inch-worm' structure of walking-pneumonia bacterium 2Jefferson researchers uncover new way nature turns genes on and off 2A transplant in time 2
CQCS kit for etra KR 4i , (other units)....
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
...
Biology Products: